Novo Nordisk stock loses 0.29 percent pre-market to EUR 33.91
Published on 10/08/2026 at 08:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk stock was EUR 33.91 pre-market at 8:29 a.m. CEST on October 8, 2026, down 0.29 percent versus the EUR 34.01 prior close at Lang & Schwarz on October 7, 2026.
Pre-market trading
Lang & Schwarz showed a bid of EUR 33.89 and an ask of EUR 33.92 for Novo Nordisk. The quote was recorded before the Xetra session, which begins at 9:00 a.m. CEST. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Novo Nordisk stock.
Strategic ambitions
In a September 21, 2026, press release distributed by Globenewswire via Ritzau, Novo Nordisk said its Capital Markets Day would present strategic ambitions for 2030. The company highlighted plans to launch more than five multi-blockbusters by 2030 and to serve more than 60 million patients globally by that year. It also outlined an ambition for more than DKK 150 billion in risk-adjusted pipeline sales in 2035. The release said the ambitions were based on a 2026 baseline and did not constitute financial guidance.
Trading context
The company’s release described a strategy spanning research and development, commercial operations, manufacturing and supply, and financial priorities. It also said Novo Nordisk aimed to maintain a broadly stable operating margin and an attractive dividend per share, with the ambitions based on adjusted metrics.
